Established on September 3, 2007, Shanghai Tonglian Pharmaceutical Co., Ltd. is a new pharmaceutical enterprise tailored by Tonglian Group for the new drug clindamycin. As an important part of the integration of R&D, production and sales of Tonglian Group, the company mainly focuses on the treatment of patients with skin diseases, tumors and infections. At present, the company is small in scale and low in share capital, and the limited liability company controlled by natural persons has not yet been listed.
Tonglian Pharmaceutical Company Information:
Legal Representative: JUNG WOO.
Date of establishment: September 2007-13
Registered capital: 360 million yuan.
Administrative Division: Songjiang District, Shanghai
Enterprise type: limited liability company (natural person investment or holding)
Industry: pharmaceutical manufacturing:
Scope: Tablets and ointments, engaged in the import and export of goods and technologies.
Registered address: No.55 Xinfei Road, Songjiang District, Shanghai
Business period: September 2007-13 to September 2057-12.
Audit/annual inspection date: September 2007-13
Registration authority: Songjiang District Market Supervision Bureau
Conditions for listing the company's shares:
Approved by the the State Council Securities Regulatory Authority, the stock has been publicly issued;
2. The total share capital of the company is not less than 30 million yuan;
3. The publicly issued shares account for more than 25% of the total shares of the company; If the company's total share capital exceeds 400 million yuan, the proportion of publicly issued shares exceeds 65,438+00%;
The company has no major illegal acts in the past three years, and there are no false records in the financial and accounting reports.